Latest News
The Role of the Pharmacist after Dobbs v. Jackson Women’s Health Organization Ruling
The Hematology/Oncology Pharmacy Association (HOPA) is committed to optimizing cancer care for all individuals. The recent U.S. Supreme Court decision, which overturned Roe v. Wade, imposes a significant barrier to the oncology community’s ability to ens
National Survey on the Effect of Oncology Drug Shortages in Clinical Practice: A Hematology Oncology Pharmacy Association Survey
Oncology drug shortages often result in disruptions in the timing of chemotherapy treatments, alterations in the dose or regimen administered, or even missed doses when alternative agents are unavailable. The purpose of this survey was to characterize the
The Role of the Pharmacist after Dobbs v. Jackson Women’s Health Organization Ruling
The Hematology/Oncology Pharmacy Association (HOPA) is committed to optimizing cancer care for all individuals. The recent U.S. Supreme Court decision, which overturned Roe v. Wade, imposes a significant barrier to the oncology community’s ability to ens
Streamfield variant - default Image. Lorem ipsum dolor sit amet consectetur. Accumsan rutrum egestas ultrices.
Lorem ipsum dolor sit amet consectetur. Mauris nisi pulvinar sem pharetra maecenas egestas aenean tortor. Cras vulputate sem volutpat libero. Duis nec augue laoreet in odio est malesuada ut facilisi. Feugiat mauris lorem sed pellentesque mauris et et. In
Learn More
Streamfield variant - default Image. Lorem ipsum dolor sit amet consectetur. Accumsan rutrum egestas ultrices.
Streamfield variant - Banner (larger) image. Lorem ipsum dolor sit amet consectetur.
Learn More
Streamfield variant - no image, centered text. Lorem ipsum dolor sit amet consectetur. Accumsan rutrum egestas ultrices.
Lorem ipsum dolor sit amet consectetur. Lacus tristique et integer nulla vitae cursus nunc vel. Eget quam lobortis sit diam porttitor velit. Ut velit dignissim turpis neque lectus duis nibh. Nibh tellus sodales odio urna.
Learn MoreExplore more from HOPA
Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer
The data from this trial confirm that FTD–TPI plus bevacizumab is an effective treatment option for patients with refractory metastatic colorectal cancer, irrespective of mutational status, which side the tumor is on, and whether patients have previously
